A cytotoxicity pass only answers one question: whether the tested extract or material caused cell damage under the conditions used. It does not prove full biological safety, and it can be misleading if the extraction conditions are weak or unrepresentative.
That is why reviewers care not only about the final result, but also about how the test was designed, whether the finished device was represented, and whether a waiver or chemistry-based rationale would have been more appropriate.
Cytotoxicity is the most frequently run biological test for medical devices, but it is also one of the easiest results to over-interpret. A good file needs to explain where the result fits in the broader biological evaluation rather than presenting it as the whole story.
ISO 10993-5 in the Biological Evaluation Framework
ISO 10993-5 addresses whether a device material or its extracts cause cell death or significantly inhibit cell growth in an in vitro system. It is a useful screening endpoint, but only one endpoint. A clean cytotoxicity result does not automatically answer sensitization, irritation, genotoxicity, systemic toxicity, hemocompatibility, or chronic-risk questions.
What Cytotoxicity Testing Actually Measures
The common methods are extract testing, direct contact, and indirect contact such as agar diffusion. In practice, extract testing is often the most relevant because it reflects what substances may migrate from the device into a patient-facing environment.
- Extract test: the device or material is extracted into a test medium, then the extract is applied to cells such as L929 fibroblasts.
- Direct contact: the material is placed directly on the cell layer.
- Indirect contact: the device is separated from the cells by an intermediate layer such as agar.
A pass means the tested extract or material did not cause unacceptable cell damage under those conditions. It does not mean the device is globally safe for all biological endpoints.
How to Interpret the Cell-Viability Result
In ISO 10993-5-style cytotoxicity contexts, interpretation is usually built around whether cell viability is meaningfully reduced compared with untreated controls. Peer-reviewed interlaboratory work on ISO 10993-5 describes the common cytotoxicity threshold as more than 30% reduction in cell viability relative to the control. That threshold is useful, but it is not the whole story: the extraction design, cell model, exposure time, and finished-device representation still decide whether the result is persuasive for a real regulatory file.
What a Cytotoxicity Result Does Not Tell You
Even a clear passing result leaves major gaps if it is treated as a complete safety answer. Cytotoxicity does not resolve questions about sensitization potential, genotoxic compounds, systemic toxicants, carcinogenicity, or endpoint interactions that may matter for longer-contact or more complex devices.
Why Extraction Conditions Matter So Much
The extraction solvent, temperature, time, and surface-area-to-volume ratio can change the result materially. Published interlaboratory and biomaterial studies show that ISO 10993-5 test outcomes can vary when extraction and cell-culture conditions differ. If the extraction is not appropriate for the material and use case, the test may under-represent what the patient could actually be exposed to. That is why notified bodies and FDA reviewers often look beyond the word "pass" and ask whether the extraction conditions were suitable for the device's intended use.
When Cytotoxicity Can Be Waived
A new cytotoxicity test is not always necessary. The endpoint can sometimes be waived when the device materials are well characterized, the chemistry profile is well understood, and the evidence actually represents the current finished device state.
- Well-characterized materials: strong published evidence or prior device data may already address the endpoint.
- Chemistry-based support: chemical characterization and toxicological assessment can show no cytotoxic concern above meaningful thresholds.
- True device equivalence: a waiver may be supportable when the current device genuinely matches an already-evaluated configuration.
Common Documentation Failures
- Treating cytotoxicity as the whole evaluation: the BER stops at a pass/fail statement instead of explaining endpoint context.
- Weak extraction rationale: the file does not explain why the chosen conditions represent worst-case use.
- Testing the wrong article: the evidence comes from a raw material or non-final configuration rather than the finished device state.
- Waiver language without support: the endpoint is omitted with a generic statement instead of a real scientific argument.
Cytotoxicity is often important, but it should be presented as one piece of the endpoint strategy. The strongest files explain why the result is meaningful, how the extraction was chosen, and how the endpoint fits into the larger biological evaluation plan.
Where Cytotoxicity Fits in a Strong BEP or BER
In a strong BEP, cytotoxicity is an endpoint decision supported by contact type, duration, materials, and available evidence. In a strong BER, the result or waiver is interpreted in context and linked to the overall biological safety conclusion rather than left as a standalone lab outcome.
Key References
- ISO 10993-5:2009 for in vitro cytotoxicity test methods; ISO lists the 2009 edition as confirmed in 2022.
- FDA biocompatibility endpoint framework showing cytotoxicity as one endpoint within broader biological evaluation.
- Gruber & Nickel, 2023, an ISO 10993-5 interlaboratory study highlighting result variability and the role of test conditions.
- Jablonska et al., 2021, showing that cytotoxicity test conditions can significantly affect results for degradable biomaterials.
Why this perspective is practical
MedDev Advisory focuses on ISO 10993 biological evaluation, FDA reviewer-facing files, EU MDR technical documentation, and selected CDSCO strategy work. Arvind Rathore's background includes implantable biosensor research at IIT Kanpur and as a Marie Skłodowska-Curie Fellow at INSERM, including hands-on ISO 10993-aligned biocompatibility testing, cytotoxicity, sterilization effects, oxidative stress, and biomaterial-cell interaction work. Read more about Arvind Rathore.
Need help deciding whether cytotoxicity should be tested, waived, or interpreted differently in your file?
Use the next step that fits best: discuss the project directly or continue through the insights library for related guidance.